These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2006-004768-30 Traitement de première ligne des lymphomes du manteau de patients agés de 65 à 80 ans. Evaluation de l'efficacité, de la toxicité et de facteurs pronostiques moléculaires de l'inhibiteur du protéasome... not-yet-due
Listed as ongoing, but also has a completion date 2007-000327-18 Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previousl... 2013-01-07 bad-data
Ongoing 2007-002414-19 Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chimio... not-yet-due
Not reported 2007-004644-70 Etude de phase III ouverte, randomisée portant sur l’intérêt d’un traitement d’entretien par rituximab en post-autogreffe dans le traitement des lymphomes à cellules du manteau chez des patients âgés ... 2019-04-15 due-trials
Ongoing 2007-005580-95 An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follicula... not-yet-due
Ongoing 2007-007056-33 An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) mai... not-yet-due
Ongoing 2009-010017-72 Bendamustine in patients with refractory or relapsed T-cell lymphoma. A phase II multicenter study “BENTLY” not-yet-due
Ongoing 2015-000929-37 EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy ... not-yet-due